Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.

Takeda had hoped that Eohilia would be the first-ever treatment for EoE, but that crown was snatched by Sanofi and Regeneron’s injectable antibody Dupixent (dupilumab), which was approved for ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with ...

Suggested treatments for eosinophilic esophagitis include proton pump inhibitors, topical steroids, empiric food elimination diet, biologics, endoscopic dilation. HealthDay News — In a clinical ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...